Pieris Pharmaceuticals Company Profile (NASDAQ:PIRS)

About Pieris Pharmaceuticals

Pieris Pharmaceuticals logoPieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PIRS
  • CUSIP:
Key Metrics:
  • Previous Close: $2.03
  • 50 Day Moving Average: $2.00
  • 200 Day Moving Average: $1.68
  • 52-Week Range: $1.30 - $2.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.21
  • P/E Growth: 0.00
  • Market Cap: $85.69M
  • Outstanding Shares: 43,058,000
  • Beta: 1.91
Profitability:
  • Net Margins: -364.96%
  • Return on Equity: -60.26%
  • Return on Assets: -47.47%
Debt:
  • Current Ratio: 4.13%
  • Quick Ratio: 4.13%
Additional Links:
Companies Related to Pieris Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Pieris Pharmaceuticals (NASDAQ:PIRS) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.33 (318.76% upside)

Analysts' Ratings History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Show:
DateFirmActionRatingPrice TargetDetails
9/28/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$10.00View Rating Details
9/28/2016Roth CapitalReiterated RatingBuy$6.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$10.00 -> $9.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Pieris Pharmaceuticals (NASDAQ:PIRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/20/2017        
8/10/2016Q216($0.15)($0.14)$1.07 millionViewN/AView Earnings Details
5/12/2016Q116($0.12)($0.10)ViewN/AView Earnings Details
3/23/2016Q415($0.12)($0.07)$3.27 million$2.14 millionViewN/AView Earnings Details
11/12/2015Q315($0.11)($0.10)ViewN/AView Earnings Details
8/13/2015Q215($0.14)($0.12)$160.24 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.62 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.03$0.03$0.03
Q2 20162($0.16)($0.12)($0.14)
Q3 20162($0.14)($0.12)($0.13)
Q4 20163($0.15)($0.12)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pieris Pharmaceuticals (NASDAQ:PIRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Insider Ownership Percentage: 2.43%
Institutional Ownership Percentage: 47.58%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/14/2016Louis MatisSVPBuy10,000$1.70$17,000.00View SEC Filing  
6/13/2016Darlene M Deptula-HicksCFOBuy5,000$1.66$8,300.00View SEC Filing  
6/13/2016Stephen S YoderCEOBuy6,000$1.68$10,080.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Pieris Pharmaceuticals (NASDAQ:PIRS)
DateHeadline
News IconAre Analysts Optimistic About Where Pieris Pharmaceuticals Inc (NASDAQ:PIRS) is Heading? - Winfield Review (NASDAQ:PIRS)
winfieldreview.com - February 24 at 8:30 AM
News IconTechnical Trading: Focus on Shares of Pieris Pharmaceuticals Inc (PIRS) - Rives Journal (NASDAQ:PIRS)
rivesjournal.com - February 15 at 4:29 AM
marketexclusive.com logoPIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) Files An 8-K Termination of a Material Definitive Agreement (NASDAQ:PIRS)
marketexclusive.com - February 8 at 8:12 PM
biz.yahoo.com logoPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors (NASDAQ:PIRS)
us.rd.yahoo.com - February 8 at 8:12 PM
finance.yahoo.com logoPieris Pharmaceuticals to Present at the Bio CEO Investor Conference on February 13th at 1:30 pm EST (NASDAQ:PIRS)
finance.yahoo.com - February 8 at 8:12 PM
streetinsider.com logoPieris Pharma (PIRS) CFO to Resign - StreetInsider.com (NASDAQ:PIRS)
www.streetinsider.com - February 8 at 2:04 AM
streetinsider.com logoPieris Pharma (PIRS) CFO to Resign (NASDAQ:PIRS)
www.streetinsider.com - February 7 at 9:02 PM
us.rd.yahoo.com logoPieris Announces Management Transition (NASDAQ:PIRS)
us.rd.yahoo.com - February 7 at 9:02 PM
News IconStock Spotlight: Looking at the Levels for Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - The Tribune (NASDAQ:PIRS)
lakecitytribune.com - January 31 at 8:27 PM
News IconUnder the Microscope We Place Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - January 31 at 8:27 PM
News IconNear-Term, Can This Stock Move the Needle: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - January 31 at 12:58 AM
News IconHigh Volatility Moving the Needle For Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Wall Street Beacon (NASDAQ:PIRS)
wsbeacon.com - January 31 at 12:58 AM
News IconEarnings in Full Force, Analysts Take Aim at Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Wall Street Beacon (NASDAQ:PIRS)
wsbeacon.com - January 28 at 5:41 AM
News IconIndicator Level Summary for Pieris Pharmaceuticals Inc (PIRS) - Sherwood Daily (NASDAQ:PIRS)
sherwooddaily.com - January 28 at 5:41 AM
News IconHigh Volatility Creating Buzz Mid-Session For Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Wall Street Beacon (NASDAQ:PIRS)
wsbeacon.com - January 28 at 5:41 AM
News IconStock Going Gangbusters Mid-Session: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Wall Street Beacon (NASDAQ:PIRS)
wsbeacon.com - January 28 at 5:41 AM
News IconMonitoring Relative Strength Index Values for Pieris Pharmaceuticals Inc (PIRS) - Sherwood Daily (NASDAQ:PIRS)
sherwooddaily.com - January 26 at 12:53 AM
News IconPriming The Pump: Stock Volatility Spotted in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Wall Street Beacon (NASDAQ:PIRS)
wsbeacon.com - January 24 at 12:34 AM
News IconWatching the Charts on Pieris Pharmaceuticals Inc (PIRS) - Sherwood Daily (NASDAQ:PIRS)
sherwooddaily.com - January 21 at 1:07 AM
News IconTrading Scope: Indicator Review for Pieris Pharmaceuticals Inc (PIRS) - Sherwood Daily (NASDAQ:PIRS)
sherwooddaily.com - January 20 at 1:17 AM
News IconAstute Investors Are Taking a Look at Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - January 20 at 1:17 AM
News IconTrading Watch: ADX and CCI Review for Pieris Pharmaceuticals Inc (PIRS) - Sherwood Daily (NASDAQ:PIRS)
sherwooddaily.com - January 19 at 12:50 AM
News IconMarching to the Beat of Their Own Drum, Update on Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - January 19 at 12:50 AM
News IconGearing Up For a Bull Run? Analysts Weigh in on Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Wall Street Beacon (NASDAQ:PIRS)
wsbeacon.com - January 18 at 8:36 AM
News IconInvestor Guide: Checking on Indicators for Pieris Pharmaceuticals Inc (PIRS) - Sherwood Daily (NASDAQ:PIRS)
sherwooddaily.com - January 18 at 12:36 AM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Wall Street Beacon (NASDAQ:PIRS)
wsbeacon.com - January 18 at 12:36 AM
News IconKnuckling Down on Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - January 18 at 12:36 AM
News IconToday's Rating Sentiment Change: How Many Pieris Pharmaceuticals Inc (NASDAQ:PIRS)'s Analysts Are Bearish? - Fair View Times (NASDAQ:PIRS)
fairviewtimes.com - January 14 at 1:24 AM
News IconCheap Stock Alert & Update on Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - January 14 at 1:24 AM
News IconRisky Play or Bargain? Update on Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - January 13 at 12:53 AM
News IconWill The Needle Move For Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:PIRS)
wsbeacon.com - January 13 at 12:53 AM
News IconIs this Stock Under $5 a Bargain: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - January 11 at 7:55 PM
biz.yahoo.com logoPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:PIRS)
us.rd.yahoo.com - January 9 at 7:55 PM
us.rd.yahoo.com logo7:48 am Pieris Pharmaceuticals provides 2017 milestones in slide presentation (NASDAQ:PIRS)
us.rd.yahoo.com - January 9 at 7:55 PM
News IconPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) announced a broad collaboration in immuno-oncology (NASDAQ:PIRS)
myhealthbowl.com - January 8 at 6:56 PM
News IconAlexion Pharmaceuticals (NASDAQ:ALXN)- Hot Stocks Retreats on New Development: Pieris Pharmaceuticals ... - Street Wise Report (press release) (blog) (NASDAQ:PIRS)
streetwisereport.com - January 6 at 7:56 PM
News IconAre Investors Shying Away from Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - January 6 at 5:04 AM
News IconPieris Pharmaceuticals Inc (NASDAQ:PIRS) Pops on Validating Collaboration - The Oracle Dispatch (NASDAQ:PIRS)
oracledispatch.com - January 6 at 5:04 AM
finance.yahoo.com logoPieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance (NASDAQ:PIRS)
finance.yahoo.com - January 6 at 12:02 AM
biz.yahoo.com logoPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and (NASDAQ:PIRS)
biz.yahoo.com - January 6 at 12:02 AM
finance.yahoo.com logo7:14 am Pieris Pharmaceuticals and Servier to jointly pursue several bispecific therapeutic programs including its' proprietary dual checkpoint inhibitor PRS-332; co to receive $31.3 mln upfront, up to $539 mln in success-based payments (NASDAQ:PIRS)
finance.yahoo.com - January 6 at 12:02 AM
finance.yahoo.com logoPieris Pharmaceuticals to Host Investor Call Today to Discuss Servier Collaboration (NASDAQ:PIRS)
finance.yahoo.com - January 6 at 12:02 AM
News Icon19 Companies Selected for the 2017 Small-Cap Biotech Watchlist - Jutia Group (press release) (blog) (NASDAQ:PIRS)
jutiagroup.com - January 5 at 1:07 AM
News IconDelving into Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - January 5 at 1:07 AM
News Icon19 Companies Selected for the 2017 Small-Cap Biotech Watchlist (NASDAQ:PIRS)
countingpips.com - January 4 at 4:59 AM
News IconBargain Hunter Investor Update on Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - December 31 at 8:30 AM
News IconStreetwise Investors Taking Note of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - December 29 at 7:14 PM
News IconZeroing in on Company Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - December 27 at 7:03 PM
News IconCan This Stock Price Climb The Ladder: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - December 23 at 6:43 AM
News IconBargain Hunter's Delight: What's the Latest on Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Prospect Journal (NASDAQ:PIRS)
prospectjournal.com - December 22 at 1:05 AM

Social

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Where is Pieris Pharmaceuticals' stock going? Where will Pieris Pharmaceuticals' stock price be in 2017?

3 analysts have issued 1-year price objectives for Pieris Pharmaceuticals' stock. Their predictions range from $6.00 to $10.00. On average, they anticipate Pieris Pharmaceuticals' stock price to reach $8.33 in the next twelve months.

When will Pieris Pharmaceuticals announce their earnings?

Pieris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 20th 2017.

Who owns Pieris Pharmaceuticals stock?

Pieris Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (16.86%). Company insiders that own Pieris Pharmaceuticals stock include Darlene M Deptula-Hicks, Louis Matis and Stephen S Yoder.

How do I buy Pieris Pharmaceuticals stock?

Shares of Pieris Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Pieris Pharmaceuticals stock cost?

One share of Pieris Pharmaceuticals stock can currently be purchased for approximately $1.99.

Pieris Pharmaceuticals (NASDAQ:PIRS) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Earnings History Chart

Earnings by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Dividend History Chart

Dividend Payments by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Last Updated on 2/24/2017 by MarketBeat.com Staff